Oral valganciclovir prophylaxis in kidney transplant recipients

Details

Serval ID
serval:BIB_0A3A5D924FE1
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
Oral valganciclovir prophylaxis in kidney transplant recipients
Title of the conference
12th International Society for infectious Diseases
Author(s)
Manuel O., Fellay J., Venetz J.P., Sturzenegger N., Meylan R., Pascual M.
Address
Lisbon, Portugal, June 15-18, 2006
ISBN
1201-9712
Publication state
Published
Issued date
2006
Peer-reviewed
Oui
Volume
10
Series
International Journal of Infectious Diseases
Pages
S16
Language
english
Notes
Publication type : Meeting Abstract
Abstract
Background: Immunosuppressive and antivira[ prophy[
actic drugs are needed to prevent acute rejection
and infection after organ transplantation.
We assessed the effectiveness of a new combined
regimen introduced at our transplantation center.
Methods: We reviewed at[ consecutive patients
who underwent kidney transplantation at our institution
over a 5.5-year period, with a follow-up
of at [east 6 months. Patients transplanted from
1/2000 to 3/2003 (Period 1) were compared to
patients transplanted from 4/2003 to 7/2005 (Period
2). In period 1, patients were treated with
Basi[iximab, Cic[osporin, steroids and Mycophenotate
or Azathioprine. Prophylaxis with Va[acic[
ovir was prescribed in CMV D+/R- patients; otherwise,
a preemptive antivira[ approach was used.
In period 2, immunosuppressive drugs were Basi[-
iximab, Tacro[imus, steroids and Mycopheno[ate.
A 3-month CMV prophylaxis with Va[gancic[ovir was
used, except in D-/R- patients.
Results: Sixty-three patients were transplanted in
period 1 and 70 patients in period 2. Baseline
characteristics of both groups were comparable;
in particular 17% of patients were CMV D+/R- in
period 1 compared to 23% in period 2 (p=0.67).
Acute rejection was more frequent in period 1
than in period 2 (40% of patients vs 7%, respectively
p<0.001). Nineteen patients (30%) in period
1 were diagnosed with CMV infection/disease
that required treatment, compared with 8 patients
(11.4%) in period 2 (p = 0.003). Of these 8 patients,
at[ had CMV infection/disease after discontinuation
of Va[gancic[ovir prophylaxis, 6 were D+/R- (75%),
and at[ were treated with oral Va[gancic[ovir. There
was no difference between periods in terms of
incidence of BK nephropathy, post-transplant [ymphopro[
iferative disease, graft toss, and mortality.
Conclusions: These results indicate that a 3-month
course of oral Va[gancic[ovir is very effective to
prevent CMV infection/disease in kidney transplantation.
Late-onset CMV disease is a residual problem
in D+/R- patients receiving VGC prophylaxis.
Keywords
,
Web of science
Create date
05/01/2011 10:55
Last modification date
20/08/2019 12:32
Usage data